Chronic Rhinosinusitis Trial, Not Yet Recruiting NCT07616609 Sponsor: Beijing Tongren Hospital Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Not Yet Recruiting

NCT07616609
Not Yet Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to understand what the study involves and are willing to sign a consent form agreeing to take part
  • You are between 18 and 75 years old (any gender)
  • You have been diagnosed with nasal polyps in both nostrils, meeting specific Chinese medical guidelines for this condition
  • You have had nasal congestion plus at least one other symptom (such as reduced/lost sense of smell or a runny nose) continuously for 12 weeks or more before the study screening
  • Your nasal polyps score at least 4 points total (and at least 2 points in each nostril) on a standard medical scale, both at screening and at the start of the study
  • You report moderate to severe nasal congestion or loss of smell based on a standard scoring scale, both at screening and at the start of the study
  • A CT scan of your sinuses shows a significant level of sinus involvement based on a standard scoring system
  • Your nasal polyps or blood tests show signs of a specific type of inflammation (called "type 2 inflammation"), confirmed through tissue or blood samples
  • If you have asthma, it must be stable and any inhaled steroid treatment must have been at a consistent dose for at least 4 weeks before screening, and must not exceed a certain daily amount

Who may not be able to join:

  • You have previously had any sinus or nasal surgery, including procedures to straighten the nasal passage, reduce nasal tissue, or remove polyps
  • You have a medical reason why you cannot safely receive general anaesthesia
  • You have a medical reason why you cannot receive the study drug (stapokibart)
  • You have previously been treated with any similar type of biologic medicine that targets the same part of the immune system (anti-IL-4Rα biologics)
  • You have had a nasal infection, upper respiratory tract infection, or acute asthma attack recently, or you have certain other nasal or sinus conditions such as fungal sinusitis or nasal tumours (confirm with trial site)
  • You have certain serious ongoing conditions that could affect the study results, such as cystic fibrosis or specific rare inflammatory diseases (confirm with trial site)
  • You have another serious or poorly controlled long-term illness, such as active infections, heart disease, diabetes, autoimmune disease, HIV, hepatitis B or C, tuberculosis, or cancer
  • Your liver or kidney function tests show results significantly outside the normal range
  • You have a known or suspected problem with your immune system, or have a history of certain serious infections even if they have cleared up (confirm with trial site)
  • You are pregnant, planning to become pregnant during the study, or are currently breastfeeding
  • You are of childbearing age and are not willing to use an approved method of contraception during the study
  • You have a history of alcohol or drug misuse
  • The trial doctors have another medical or personal reason they feel makes participation unsuitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mu Xian, MD, Beijing Tongren Hospital

Phone: +86 13671138761

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Beijing Tongren Hospital
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from Baseline in Nasal Polyp Score (NPS) at Week 48 Postoperatively

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov